Time to talk about timing – when to start,stop and change anti-migratory drugs in MS

Abstract

Get full access to this article

View all access options for this article.

References

Pelletier

Hafler

. Fingolimod for multiple sclerosis. N Engl J Med 2012; 366: 339–347.

Stüve

Bennett

. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007; 13: 79–95.

Cohen

Barkhof

Comi

. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010; 362: 402–415.

Kappos

Radue

O’Connor

. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010; 362: 387–401.

Rudick

Stuart

Calabresi

. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911–923.

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Hakiki

Portaccio

Giannini

. Withdrawal of fingolimod treatment for relapsing–remitting multiple sclerosis: Report of six cases. Mult Scler 2012; [in this issue].

Rinaldi

Seppi

Calabrese

. Switching therapy from natalizumab to fingolimod in relapsing–remitting multiple sclerosis: Clinical and MRI findings. Mult Scler 2012; [in this issue].

Miravalle

Jensen

Kinkel

. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol 2010; 68: 186–191.

10.

Killestein

Vennegoor

Strijbis

. Natalizumab drug holiday in multiple sclerosis: Poorly tolerated. Ann Neurol 2010; 68: 392–395.

11.

Vellinga

Castelijns

Barkhof

. Postwithdrawal rebound increase in T2 lesional activity in natalizumab-treated MS patients. Neurology 2007; 70 (13 Pt 2): 1150–1151.

12.

West

Cree

. Natalizumab dosage suspension: Are we helping or hurting? Ann Neurol 2010; 68: 395–399.

13.

O’Connor

Goodman

Kappos

. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 2011; 76: 1858–1865.

14.

Jander

Turowski

Kieseier

. Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod. Mult Scler 2012; [in this issue].

15.

Daelman

Maitrot

Maarouf

. Severe multiple sclerosis reactivation under fingolimod three months after natalizumab withdrawal. Mult Scler 2012; [in this issue].

16.

Bloomgren

Richman

Hotermans

. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med 2012; 366: 1870–1880.

17.

Krumbholz

Meinl

Kumpfel

. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350–1354.

18.

Kivisakk

Healy

Viglietta

. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology 2009; 72: 1922–1930.

19.

Castrop

Kowarik

Albrecht

. Severe multiple sclerosis relapse under fingolimod therapy: Incident or coincidence? Neurology 2012; 78: 928–930.

20.

Visser

Wattjes

Pouwels

. Tumefactive multiple sclerosis lesions under fingolimod treatment. Neurology. 2012 Oct 3. [Epub ahead of print].